Volume 7 Supplement 1
Effect of PilE4 of Francisella tularensis subsp. holarctica (live vaccine strain) to brain endothelium
© Bencurova et al.; licensee BioMed Central Ltd. 2014
Published: 1 April 2014
Francisella are rare, highly infectious vector-borne bacteria, which infect more than 250 host species, including humans. Francisella are able to invade multiple organs in the host body, such a skin, liver, lung and central nervous system. To invade various organs, Francisella have to cross the cell linings like endothelial barriers. Interaction with endothelial cells is multistage process, which includes adhesion and activation of signaling events. Our previous work has shown that Francisella tularensis subsp. holarctica Live Vaccine Strain (LVS) interacts and adhere to endothelial cells through PilE4 and Intercellular adhesion molecule 1(ICAM-1) interaction. To corroborate consequences of PilE4 adhesion to endothelial cells, we incubated brain microvascular endothelial cells with recombinant PilE4 protein and assessed the regulation of several genes with qRT-PCR. Results showed that PilE4 upregulated the expression of adhesion molecules (ICAM-1 and PECAM-1), matrix metalloproteases (MMP 1, MMP 3 and MMP 9) and molecules that are involved in pathogen recognition (TLR-6, MyD88, IRAK-1 and TRAF-6) in brain endothelium. On the other hand, we found down regulation of interleukins and NF-kB. Inhibition of NF-kB indicates that Francisella might use NF-kB subversion mechanism to evade immune response. This mechanism is described in other pathogens such as Listeria and Yersinia. Previous studies have showed that matrix-metalloprotases, mainly MMP-9, is crucial to disrupt cytoskeleton of brain endothelium to increase the permeability of BBB. In summary, work reveal hidden aspects of invasion and translocation of Francisella across the brain endothelium, that offers new insight into the pathobiology of neuroinvasion of Francisella.
This work was supported by APVV-0036/10, VEGA-1/0054/12 and structural funds for centers of excellence-26220120002 (INFEKTZOON). E.B and L.B. are funding for post-doctoral studies from ITMS 26220220185.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.